Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Other Non-Current Assets (2016 - 2025)

Traws Pharma (TRAW) has disclosed Other Non-Current Assets for 14 consecutive years, with $104000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 10300.0% year-over-year to $104000.0; the TTM value through Dec 2025 reached $104000.0, up 10300.0%, while the annual FY2025 figure was $104000.0, 10300.0% up from the prior year.
  • Other Non-Current Assets hit $104000.0 in Q4 2025 for Traws Pharma, down from $240000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $244000.0 in Q2 2025 and bottomed at $1000.0 in Q3 2022.
  • Average Other Non-Current Assets over 5 years is $56400.0, with a median of $5500.0 recorded in 2021.
  • Year-over-year, Other Non-Current Assets tumbled 93.33% in 2021 and then soared 24300.0% in 2025.
  • Traws Pharma's Other Non-Current Assets stood at $10000.0 in 2021, then plummeted by 90.0% to $1000.0 in 2022, then changed by 0.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024, then skyrocketed by 10300.0% to $104000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $104000.0, $240000.0, and $244000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.